Biotechnology

SINOMAB BIO-B

China Antibody-B Announces 2025 Annual Loss of 105 Million RMB

SINOMAB BIO-B released FY2025 9 Months Earnings on March 23 (BJT), actual revenue HKD 5.245 M, actual EPS HKD -0.0735

SINOMAB BIO-B released FY2025 Q3 earnings on March 23, 2026 (BJT) with actual revenue of HKD -5.347 M and EPS of HKD -0.0222

SINOMAB BIO-B released FY2025 earnings on March 23 During-Market (BJT), actual revenue HKD 0, actual EPS HKD -0.0935

SINOMAB BIO-B released FY2025 Q4 earnings on March 23 During-Market BJT, actual revenue HKD -5.439 M, actual EPS HKD -0.0225

SINOMAB BIO-B to Release FY2025 Earnings Report on March 23 During-Market (BJT)

China Antibody-B Reaches New High, Continues to Optimize Operational Quality

China Antibody reports reduced loss of RMB 49.821 million for the first half of 2025

SINOMAB BIO-B released FY2025 Q1 earnings on August 29 (BJT), actual revenue HKD 5.238 M, actual EPS HKD -0.0243

China Biology-B Reports Strong Mid-Year Earnings and Advances in Core Drug Pipeline

China Antibody-B Completes Placement of 24,965,400 Shares

SINOMAB BIO-B released FY2025 Semi-Annual Earnings on August 29 During-Market BJT, actual revenue HKD 10.59 M, actual EPS HKD -0.0492

SINOMAB BIO-B released FY2025 Q2 earnings on August 29 During-Market (BJT), actual revenue HKD 5.353 M, actual EPS HKD -0.0248

SINOMAB BIO-B FY2025 Semi-Annual Earnings Release on August 29, 2025 (BJT)

China Antibody-B issues 157 million shares to subscribers

China Biology Antibody-B and SYSU-IAS Sign Biomedical R&D Cooperation Agreement

China Antibody-B Issuing New Shares and Adjusting Drug Development Plan

China Antibody-B Issues New Shares to Raise Funds

China Antibody-B Withdraws BLA Application for Shuzilimab for RA

China Antibody-B Appoints New Independent Non-Executive Directors

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

03681

SinoMab BioScience Limited announced that Dr. Shui On Leung, its Executive Director and CEO, was invited to present at the 2026 LifeArc Translational Science Summit in London. He delivered a keynote speech on the company's R&D strategies for autoimmune diseases, highlighting the progress of its flagship drug SM17. The summit focused on bridging scientific research and clinical application, discussing advancements in antibody drugs and gene therapy. Dr. Leung's invitation reflects international recognition of SinoMab's innovative efforts in immunotherapy and provides an opportunity to strengthen global partnerships.

Asian Corporate Newswire

Dr. Shui On Leung Invited to the 2026 LifeArc Translational Science Summit in the UK

159859

512290

516930

516820

516500

159615

159837

SinoMab Bioscience Sets Out Board and Committee Structure

Tip Ranks

Tianhong CNI BIOMEDICINE ETF

Guotai CSI Bio-medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Huaan Hang Seng Biotech ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ChinaAMC CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

China Southern Hang Seng Biotech ETF(QDII)

E Fund CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

SinoMab Bioscience Sets Out Board and Committee Structure

SinoMab BioScience Limitedreported a 43.3% decrease in annual losses for 2025, with losses of approximately RMB105 million, down from RMB185 million in 2024. The company raised about HK$493.7 million in net proceeds to support R&D, particularly for its first-in-class monoclonal antibody SM17, which targets IL-25 for treating atopic dermatitis and inflammatory bowel disease. Positive Phase 1b results for SM17 in atopic dermatitis were reported, and an IND for inflammatory bowel disease was approved in February 2026. The company continues to advance its early-stage pipeline.

SinoMabAchieves Approximately 43.3% Year-over-Year Decrease in Annual Losses for 2025, Marking Significant Progress in Pipeline Advancement

SINOMAB BIO-B announced its financial results for the fiscal year 2025, reporting a loss of 105 million RMB, compared to a loss of 185 million RMB in the previous year; the loss per share is 0.09 RMB. No final dividend will be distributed. There were no confirmed revenues during the year

AASTOCKS

"Performance" SINOMAB BIO-B's annual loss narrowed to 105 million RMB

SinoMab Bioscience Ltd. has received approval from China's National Medical Products Administration for an investigational new drug application to test SM17 in inflammatory bowel disease, expanding its use beyond atopic dermatitis. The company completed a Phase I study and plans to advance to Phase II trials. SM17 is a humanized monoclonal antibody targeting the IL-25 receptor, offering a new option for ulcerative colitis and Crohn's disease. Analysts currently rate the stock as a Sell with a price target of HK$1.50.

SinoMab Wins China IND Nod to Expand SM17 Into Inflammatory Bowel Disease

02575

01228

百奥赛图-B

02126

08622

On October 27th, the Hong Kong stock market saw significant gains in the pharmaceuticals and biotechnology sector. XUANZHUBIO-B rose nearly 19%, CANBRIDGE-B increased over 14%, SINOMAB BIO-B climbed over 11%, BAIOO SAI TU-B and HUAKANG BIOMED both surged over 9%, and JW THERAP-B rose over 8%

Zhitong

XUANZHUBIO-B

CANBRIDGE-B

JW THERAP-B

JOYZYME GROUP

The Hong Kong stock market's pharmaceutical and biotechnology sector leads in gains

SINOMAB BIO-B's stock price rose over 7% in the afternoon, with an increase of 6.33% as of the time of publication, trading at HKD 1.68, with a transaction volume of HKD 11.7838 million. The company announced that the bridging study for the subcutaneous injection formulation of SM17 has successfully completed the administration to the first cohort of healthy subjects, with all subjects tolerating well and no adverse events reported. The study aims to investigate the safety, tolerability, and pharmacokinetic characteristics of SM17, with recruitment expected to be completed by November 2025 and follow-up completed by March 2026. SM17 is the world's first humanized IgG4-κ monoclonal antibody, with the potential to treat skin inflammation

Understanding the Market | SINOMAB BIO-B rose over 7% in the afternoon as the bridging study for the subcutaneous injection formulation of SM17 in China completed dosing of the first cohort of healthy subjects

SINOMAB BIO-B announced that the bridging study of the subcutaneous injection formulation of SM17 has successfully completed the administration to the first cohort of healthy subjects, with all subjects tolerating well and no adverse events reported. The study aims to investigate the safety, tolerability, and pharmacokinetic characteristics of SM17, planning to recruit 30 healthy subjects, with recruitment expected to be completed by November 2025 and follow-up to be completed by March 2026. SM17 is a novel humanized IgG4-κ monoclonal antibody targeting the type II allergic reaction pathway, with significant market demand

SINOMAB BIO-B: The bridging study of the subcutaneous injection formulation SM17 in China has completed the administration to the first cohort of healthy subjects

According to the Zhitong Finance APP, SINOMAB BIO-B announced that Zhou Yuyan has resigned from the position of company secretary, effective from October 8, 2025. The board also announced that Lai Weiqi has been appointed as the company secretary to replace Zhou Yuyan, effective from October 8, 2025

SINOMAB BIO-B: Lai Weiqi has been appointed as the company secretary

SINOMAB BIO-B(03681.HK)

Dr. Shui On Leung Invited to the 2026 LifeArc Translational Science Summit in the UK

SinoMab Bioscience Sets Out Board and Committee Structure

SinoMabAchieves Approximately 43.3% Year-over-Year Decrease in Annual Losses for 2025, Marking Significant Progress in Pipeline Advancement

"Performance" SINOMAB BIO-B's annual loss narrowed to 105 million RMB

SinoMab Wins China IND Nod to Expand SM17 Into Inflammatory Bowel Disease

The Hong Kong stock market's pharmaceutical and biotechnology sector leads in gains

Understanding the Market | SINOMAB BIO-B rose over 7% in the afternoon as the bridging study for the subcutaneous injection formulation of SM17 in China completed dosing of the first cohort of healthy subjects

SINOMAB BIO-B: The bridging study of the subcutaneous injection formulation SM17 in China has completed the administration to the first cohort of healthy subjects

SINOMAB BIO-B: Lai Weiqi has been appointed as the company secretary